Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The companies said the analysis identified priority cancer indications for Rakovina’s brain-penetrant ATR inhibitor program, using the EMphora platform to inform further research.
Rakovina Therapeutics and Celvion Therapeutics completed an AI analysis identifying priority cancer indications for their brain-penetrant ATR inhibitor program.
Rakovina Therapeutics and Celvion Therapeutics completed an AI analysis identifying priority cancer indications for their brain-penetrant ATR inhibitor program.